It's time now to go inside out on Eli Liy and the weight loss and drug space. And for that, we welcome in Lee Brown, global sector lead at Third Bridge. Okay, we've seen Eli Lilly down almost 20% over the year.It's got a little bit of a bump today. We're just seeing news this morning. It's going to build $5 billion Virginia manufacturing facility.Uh with all of that in mind, how are you looking at this uh stock now, Lee. Sam, thanks for having me on. Yeah, this is an interesting evolving story.Of course, Li ...

Core Viewpoint - The competition between Eli Lilly and Novo Nordisk in the GLP-1 obesity drug market is intensifying, particularly with the introduction of oral medications, which are seen as the next frontier in obesity treatment [1][2]. Company Analysis - Eli Lilly's oral medication has garnered attention for its ease of production and convenience, but recent trial results showed less weight loss than anticipated, prompting investors to reconsider Novo Nordisk's offerings [2][4]. - Novo Nordisk is emphasizing the greater weight loss and lower discontinuation rates observed in its trials, suggesting that their data supports the effectiveness of their oral medication [4][9]. - Analysts predict that oral medications could capture approximately 20% of the projected $80 billion market for GLP-1 obesity drugs by 2030, indicating a significant potential for growth in this segment [5]. Market Dynamics - The market for obesity treatments is expected to evolve, with oral medications potentially becoming a primary treatment method, although they may not reach the effectiveness of injectable options [5][6]. - Eli Lilly's Zepbound is positioned as the gold standard, achieving over 20% weight loss, while the oral options are anticipated to yield closer to 10% weight loss, appealing to a different segment of patients [6][7]. - Novo Nordisk is also pursuing FDA approval for cardiovascular benefits associated with its oral medication, which could enhance its market appeal [9].